keyword
MENU ▼
Read by QxMD icon Read
search

transdermal estrogen therapy

keyword
https://www.readbyqxmd.com/read/29661902/brain-structure-and-cognition-3-years-after-the-end-of-an-early-menopausal-hormone-therapy-trial
#1
Kejal Kantarci, Nirubol Tosakulwong, Timothy G Lesnick, Samantha M Zuk, Val J Lowe, Julie A Fields, Jeffrey L Gunter, Matthew L Senjem, Megan L Settell, Carey E Gleason, Lynne T Shuster, Kent R Bailey, N Maritza Dowling, Sanjay Asthana, Clifford R Jack, Walter A Rocca, Virginia M Miller
OBJECTIVE: The effects of 2 frequently used formulations of menopausal hormone therapy (mHT) on brain structure and cognition were investigated 3 years after the end of a randomized, placebo-controlled trial in recently menopausal women with good cardiovascular health. METHODS: Participants (aged 42-56 years; 5-36 months past menopause) were randomized to one of the following: 0.45 mg/d oral conjugated equine estrogen (oCEE); 50 μg/d transdermal 17β-estradiol (tE2); or placebo pills and patch for 4 years...
April 17, 2018: Neurology
https://www.readbyqxmd.com/read/29570359/progestogens-and-venous-thromboembolism-in-menopausal-women-an-updated-oral-versus-transdermal-estrogen-meta-analysis
#2
P-Y Scarabin
Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). While the route of estrogen administration is now well recognized as an important determinant of VTE risk, there is also increasing evidence that progestogens may modulate the estrogen-related VTE risk. This review updates previous meta-analyses of VTE risk in HT users, focusing on the route of estrogen administration, hormonal regimen and progestogen type. Among women using estrogen-only preparations, oral but not transdermal preparations increased VTE risk (relative risk (RR) 1...
March 23, 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29526116/menopausal-hormone-therapy-a-better-and-safer-future
#3
D A Davey
Major advances in menopause hormone therapy (MHT) hold promise in the future of better and safer care for women at and after the menopause. The principal advances are: (1) the critical window or 'window of opportunity' in the 10 years or so after the menopause, during which the benefits of MHT in healthy women exceed any risks; (2) use of transdermal instead of oral administration of estrogen to reduce the risk of venous thromboembolism; (c) investigation of the use of oral micronized progesterone (MP) and vaginal MP to prevent endometrial hyperplasia and carcinoma without any increased risk of breast cancer and venous thromboembolism in postmenopausal women receiving estrogens; vaginal MP prevents endometrial proliferation in the short term but the long-term effects in MHT remain to be established; (4) investigation into the use of intrauterine levonorgestrel-releasing devices (LNG-IUDs), which are an attractive form of MHT in perimenopausal women, providing contraception and reducing uterine bleeding, although the risk of breast cancer with LNG-IUDs requires clarification...
March 11, 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29521155/migraine-hormones-and-the-menopausal-transition
#4
M A Hipolito Rodrigues, L Maitrot-Mantelet, G Plu-Bureau, A Gompel
Migraine is a common, disabling and incapacitating headache disorder that may be triggered by many factors, such as hormones especially during the perimenopausal period, where large alterations in estradiol levels can occur. The evidence implies that hormonal fluctuations are one of the important triggers of migraine. During reproductive life and during hormonal contraception, the course of migraine can be impacted. Different types of migraine with and without aura can be variously influenced by hormones. Migraine can constitute a risk factor for stroke and this must be taken in account for menopause hormone therapy...
March 9, 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29520604/estrogen-therapy-for-osteoporosis-in-the-modern-era
#5
REVIEW
V A Levin, X Jiang, R Kagan
Menopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures. Osteoporotic fractures lead to substantial morbidity and mortality, and are considered one of the largest public health priorities by the World Health Organization (WHO). It is therefore essential for menopausal women to receive appropriate guidance for the prevention and management of osteoporosis. The Women's Health Initiative (WHI) randomized controlled trial first proved hormonal therapy (HT) reduces the incidence of all osteoporosis-related fractures in postmenopausal women...
March 8, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29512784/transdermal-estrogen-gel-and-oral-aspirin-combination-therapy-improves-fertility-prognosis-via-the-promotion-of-endometrial-receptivity-in-moderate-to-severe-intrauterine-adhesion
#6
Yugang Chi, Ping He, Li Lei, Yi Lan, Jianguo Hu, Ying Meng, Lina Hu
Intrauterine adhesion (IUA) is one of the most common gynecological diseases in women of reproductive age. IUA, particularlyin moderate to severe forms, accounts for a large percentage of infertility cases. Clinically, the first‑line treatment strategy for IUA is transcervical resection of adhesion (TCRA), followed by adjuvant postoperative treatment. Estrogen is one of the classic chemotherapies used following TCRA and contributes to preventing re‑adhesion following surgery. However, estrogen has limited effects in promoting pregnancy, which is the ultimate goal for IUA management...
March 6, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29508091/current-treatment-options-headache-related-to-menopause-diagnosis-and-management
#7
REVIEW
Clinton G Lauritsen, Abigail L Chua, Stephanie J Nahas
PURPOSE OF REVIEW: Menopause is a life-changing event in numerous ways. Many women with migraine hold hope that the transition to the climacteric state will coincide with a cessation or improvement of migraine. This assumption is based mainly on common lay perceptions as well as assertions from many in the healthcare community. Unfortunately, evidence suggests this is far from the rule. Many women turn to a general practitioner or a headache specialist for prognosis and management. A natural instinct is to manipulate the offending agent, but in some cases, this approach backfires, or the concern for adverse events outweighs the desire for a therapeutic trial, and other strategies must be pursued...
March 6, 2018: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29472893/late-onset-puberty-induction-by-transdermal-estrogen-in-turner-syndrome-girls-a-longitudinal-study
#8
Aneta Monika Gawlik, Magdalena Hankus, Kamila Szeliga, Aleksandra Antosz, Tomasz Gawlik, Kamil Soltysik, Agnieszka Drosdzol-Cop, Krzysztof Wilk, Grzegorz Kudela, Tomasz Koszutski, Ewa Malecka-Tendera
Objective: Estrogen replacement therapy (ERT) for Turner syndrome (TS) is a widely discussed topic; however, the optimal model of ERT for patients with delayed diagnosis and/or initiation of therapy is still unclear, mainly due to insufficient data. We present the results of a prospective observational single-center study in which the efficacy of late-onset puberty induction by one-regimen transdermal ERT in TS girls was evaluated. Methods: The analysis encompassed 49 TS girls (63...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29419532/management-of-menopausal-symptoms-for-women-who-are-at-high-risk-of-thrombosis
#9
Joann V Pinkerton, Andra H James
For women at elevated risk of thrombosis, clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis. Oral menopausal hormone therapy increases the risk of venous thromboembolism by 2-fold to 3-fold. Observational studies suggest less thrombotic risk with transdermal therapies and with progesterone over synthetic progestogens (progestins), but the data are limited. Beneficial nonpharmacologic therapies include cognitive behavioral therapy and clinical hypnosis, whereas beneficial nonhormonal pharmacologic therapies include selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors...
February 6, 2018: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29381666/effects-of-oral-conjugated-equine-estrogens-with-or-without-medroxyprogesterone-acetate-on-incident-hypertension-in-the-women-s-health-initiative-hormone-therapy-trials
#10
Yael Swica, Michelle P Warren, JoAnn E Manson, Aaron K Aragaki, Shari S Bassuk, Daichi Shimbo, Andrew Kaunitz, Jacques Rossouw, Marcia L Stefanick, Catherine R Womack
OBJECTIVE: The aim of the study was to determine the effect of menopausal hormone therapy on incident hypertension in the two Women's Health Initiative hormone therapy trials and in extended postintervention follow-up. METHODS: A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers. This analysis includes the subsample of 18,015 women who did not report hypertension at baseline and were not taking antihypertensive medication. Women with an intact uterus received conjugated equine estrogens (CEE; 0...
January 29, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29274717/no-283-treatments-for-overactive-bladder-focus-on-pharmacotherapy
#11
Roxana Geoffrion
OBJECTIVE: To provide guidelines for pharmacotherapy to treat overactive bladder syndrome (OAB). OPTIONS: Pharmacotherapy for OAB includes anticholinergic (antimuscarinic) drugs and vaginal estrogen. Both oral and transdermal anticholinergic preparations are available. OUTCOMES: To provide understanding of current available evidence concerning safety and clinical efficacy of pharmacotherapy for OAB; to guide selection of anticholinergic therapy based on individual patient characteristics...
January 2018: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/29259465/is-human-chorionic-gonadotropin-supplementation-beneficial-for-frozen-and-thawed-embryo-transfer-in-estrogen-progesterone-replacement-cycles-a-randomized-clinical-trial
#12
Masahide Shiotani, Yukiko Matsumoto, Eri Okamoto, Satoshi Yamada, Yuri Mizusawa, Kohyu Furuhashi, Hiromi Ogata, Seiji Ogata, Shoji Kokeguchi
Aim: Human chorionic gonadotropin (hCG) is used frequently for luteal support in fresh in vitro fertilization cycles as it induces progesterone secretion from the ovaries after oocyte retrieval and modulates the endometrium for implantation in fresh cycles. In contrast, hCG is not usually used for the transfer of cryopreserved-thawed embryos in estrogen/progesterone replacement cycles because ovulation is suppressed. However, several studies have shown that luteinizing hormone and hCG receptors are present in the human endometrium and that hCG can directly induce the decidualization of endometrial stromal cells in vitro...
April 2017: Reproductive Medicine and Biology
https://www.readbyqxmd.com/read/29234814/hormone-therapy-for-the-primary-prevention-of-chronic-conditions-in-postmenopausal-women-us-preventive-services-task-force-recommendation-statement
#13
David C Grossman, Susan J Curry, Douglas K Owens, Michael J Barry, Karina W Davidson, Chyke A Doubeni, John W Epling, Alex R Kemper, Alex H Krist, Ann E Kurth, C Seth Landefeld, Carol M Mangione, Maureen G Phipps, Michael Silverstein, Melissa A Simon, Chien-Wen Tseng
Importance: Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined...
December 12, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29208690/aortic-hemodynamics-in-postmenopausal-women-following-cessation-of-hormone-therapy
#14
Ronée E Harvey, Maja C Johnson, Sushant M Ranadive, Michael J Joyner, Brian D Lahr, Virginia M Miller, Jill N Barnes
Central (aortic) blood pressure and aortic pulse wave characteristics are measures of cardiovascular health, predictive of cardiovascular mortality. Previous studies have compared aortic hemodynamics in women who do and do not take menopausal hormone therapy, but characteristics of these parameters following cessation of treatment have not been defined. Therefore, the purpose of this study was to define aortic pulse wave characteristics in postmenopausal women with and without a history of menopausal hormone therapy use...
December 2017: Physiological Reports
https://www.readbyqxmd.com/read/29039146/estrogen-based-hormone-therapy-in-women-with-primary-ovarian-insufficiency-a-systematic-review
#15
Nydia Burgos, Dahima Cintron, Paula Latortue-Albino, Valentina Serrano, Rene Rodriguez Gutierrez, Stephanie Faubion, Gabriela Spencer-Bonilla, Patricia J Erwin, Mohammad Hassan Murad
PURPOSE: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI...
December 2017: Endocrine
https://www.readbyqxmd.com/read/28994639/migraine-menopause-and-hormone-replacement-therapy
#16
E Anne MacGregor
Perimenopause marks a period of increased migraine prevalence in women and many women also report troublesome vasomotor symptoms. Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual attacks of migraine without aura, while high estrogen levels can trigger migraine aura. Maintaining a stable estrogen environment with estrogen replacement can benefit estrogen-withdrawal migraine particularly in women who would also benefit from relief of vasomotor symptoms...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28953214/clinical-trials-in-menopause
#17
Kathryn I Marko, James A Simon
OBJECTIVE: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this controversy and highlight new directions specifically related to menopausal hormone therapy (HT) and vascular disease risk. METHODS: We performed a search of sentinel studies delineating the risks and benefits of HT in otherwise healthy postmenopausal women...
February 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28846767/effects-of-oral-vs-transdermal-estrogen-therapy-on-sexual-function-in-early-postmenopause-ancillary-study-of-the-kronos-early-estrogen-prevention-study-keeps
#18
MULTICENTER STUDY
Hugh S Taylor, Aya Tal, Lubna Pal, Fangyong Li, Dennis M Black, Eliot A Brinton, Matthew J Budoff, Marcelle I Cedars, Wei Du, Howard N Hodis, Rogerio A Lobo, JoAnn E Manson, George R Merriam, Virginia M Miller, Frederick Naftolin, Genevieve Neal-Perry, Nanette F Santoro, Sherman M Harman
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women...
October 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28832429/effects-of-oral-versus-transdermal-menopausal-hormone-treatments-on-self-reported-sleep-domains-and-their-association-with-vasomotor-symptoms-in-recently-menopausal-women-enrolled-in-the-kronos-early-estrogen-prevention-study-keeps
#19
Dahima Cintron, Brian D Lahr, Kent R Bailey, Nanette Santoro, Robin Lloyd, JoAnn E Manson, Genevieve Neal-Perry, Lubna Pal, Hugh S Taylor, Whitney Wharton, Fredrick Naftolin, S Mitchell Harman, Virginia M Miller
OBJECTIVE: This study determined whether two different formulations of hormone therapy (HT): oral conjugated equine estrogens (o-CEE; 0.45 mg/d, n = 209), transdermal 17β-estradiol (t-E2; 50 μg/d, n = 201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n = 243) affected sleep domains in participants of the Kronos Early Estrogen Prevention Study. METHODS: Participants completed the Pittsburgh Sleep Quality Index at baseline and during the intervention at 6, 18, 36, and 48 months...
February 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28831686/food-versus-pharmacy-assessment-of-nutritional-and-pharmacological-strategies-to-improve-bone-health-in-energy-deficient-exercising-women
#20
REVIEW
Emily A Southmayd, Adelaide C Hellmers, Mary Jane De Souza
PURPOSE OF REVIEW: The review aims to summarize our current knowledge surrounding treatment strategies aimed at recovery of bone mass in energy-deficient women suffering from the Female Athlete Triad. RECENT FINDINGS: The independent and interactive contributions of energy status versus estrogen status on bone density, geometry, and strength have recently been reported, highlighting the importance of addressing both energy and estrogen in treatment strategies for bone health...
October 2017: Current Osteoporosis Reports
keyword
keyword
95818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"